Dinaciclib

Dinaciclib (SCH-727965) is an experimental drug that inhibits cyclin-dependent kinases (CDKs). It is being evaluated in clinical trials for various cancer indications.
Dinaciclib is being developed by Merck & Co. It was granted orphan drug status by the FDA in 2011.
Role in developing neurons.
In primary cultured neurons, dinaciclib regulates neurogenesis, where it reduces expression of upper layer marker Satb2, and induces CTIP2, expressed in neurons of deeper layers. 